[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614935":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":31,"locations":38,"responsibleParty":282,"collaborators":36,"id":284,"slug":285,"hasResults":286,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":36,"eligibilityCriteria":290,"healthyVolunteers":286,"sex":291,"minAge":292,"maxAge":36,"enrollmentInfo":293,"targetDuration":36,"studyType":296,"phases":297,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":41,"whyStopped":36,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":315},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Zasocitinib Dose A or Dose B","EXPERIMENTAL","Participants assigned to zasocitinib in the either parent studies (TAK-279-PsA-3001 \\[NCT06671483\\] or TAK-279-PsA-3002 \\[NCT06671496\\]) will continue to receive zasocitinib Dose A or Dose B at the same dose, oral tablets, QD for up to Week 104.",[13],"Drug: Zasocitinib",{"label":15,"type":10,"description":16,"interventionNames":17},"Re-randomized Participants - Zasocitinib Dose A or Dose B","Participants assigned to active comparator in the parent study (TAK-279-PsA-3001 \\[NCT06671483\\]) will be re-randomized to blinded treatment with zasocitinib Dose A or Dose B, oral tablets, QD for up to Week 104.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Zasocitinib","Zasocitinib oral tablets.",[15,9],[25,26],"TAK- 279","NDI-034858",[28],{"name":29,"affiliation":5,"role":30},"Study Director","STUDY_DIRECTOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Takeda Contact","CONTACT","+1-877-825-3327",null,"medinfoUS@takeda.com",[39,61,76,91,107,122,138,154,170,186,201,216,231,244,255,265],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"First OC Dermatology Research Inc.","RECRUITING","Fountain Valley","California","92708","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-117.95367,33.70918,{"lat":51,"lon":50},[54,58],{"name":55,"role":34,"phone":56,"phoneExt":36,"email":57},"Site Contact","714-531-2966","vivian.laquer@firstocdermresearch.com",{"name":59,"role":60,"phone":36,"phoneExt":36,"email":36},"Vivian Laquer","PRINCIPAL_INVESTIGATOR",{"facility":62,"status":41,"city":63,"state":43,"zip":64,"country":45,"countryCode":46,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"The Cohen Medical Centers","Thousand Oaks","91360-3967",{"type":48,"coordinates":66},[67,68],-118.83759,34.17056,{"lat":68,"lon":67},[71,74],{"name":55,"role":34,"phone":72,"phoneExt":36,"email":73},"805-904-0982","drcohen@wmresearch.com",{"name":75,"role":60,"phone":36,"phoneExt":36,"email":36},"Shariar Cohen-Gadol",{"facility":77,"status":41,"city":78,"state":79,"zip":80,"country":45,"countryCode":46,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Denver Arthritis Clinic - Lowry","Denver","Colorado","80230",{"type":48,"coordinates":82},[83,84],-104.9847,39.73915,{"lat":84,"lon":83},[87,89],{"name":55,"role":34,"phone":36,"phoneExt":36,"email":88},"rantolini@dacdenver.com",{"name":90,"role":60,"phone":36,"phoneExt":36,"email":36},"Christopher Antolini",{"facility":92,"status":41,"city":93,"state":94,"zip":95,"country":45,"countryCode":46,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Direct Helpers Research Center","Hialeah","Florida","33012",{"type":48,"coordinates":97},[98,99],-80.27811,25.8576,{"lat":99,"lon":98},[102,105],{"name":55,"role":34,"phone":103,"phoneExt":36,"email":104},"305-828-3555","don@dhrtrials.com",{"name":106,"role":60,"phone":36,"phoneExt":36,"email":36},"Frank Don",{"facility":108,"status":41,"city":109,"state":94,"zip":110,"country":45,"countryCode":46,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"IRIS Research and Development","Plantation","33324",{"type":48,"coordinates":112},[113,114],-80.23184,26.13421,{"lat":114,"lon":113},[117,120],{"name":55,"role":34,"phone":118,"phoneExt":36,"email":119},"954-476-2338","drvalenzuela@irisrheumatology.com",{"name":121,"role":60,"phone":36,"phoneExt":36,"email":36},"Guillermo Valenzuela",{"facility":123,"status":41,"city":124,"state":125,"zip":126,"country":45,"countryCode":46,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Klein and Associates, M.D., P.A.","Hagerstown","Maryland","21740-6138",{"type":48,"coordinates":128},[129,130],-77.71999,39.64176,{"lat":130,"lon":129},[133,136],{"name":55,"role":34,"phone":134,"phoneExt":36,"email":135},"301-791-6680","ookoye@rheumdocs.com",{"name":137,"role":60,"phone":36,"phoneExt":36,"email":36},"Okechukwu Okoye",{"facility":139,"status":41,"city":140,"state":141,"zip":142,"country":45,"countryCode":46,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"Paramount Medical Research & Consulting, LLC","Middleburg Heights","Ohio","44130",{"type":48,"coordinates":144},[145,146],-81.81291,41.36144,{"lat":146,"lon":145},[149,152],{"name":55,"role":34,"phone":150,"phoneExt":36,"email":151},"440-826-0742","idiabmd@gmail.com",{"name":153,"role":60,"phone":36,"phoneExt":36,"email":36},"Isam Diab",{"facility":155,"status":41,"city":156,"state":157,"zip":158,"country":45,"countryCode":46,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"West Tennessee Research Institute","Jackson","Tennessee","38305",{"type":48,"coordinates":160},[161,162],-88.81395,35.61452,{"lat":162,"lon":161},[165,168],{"name":55,"role":34,"phone":166,"phoneExt":36,"email":167},"731-633-0145","aresearch@arthritisclinic.org",{"name":169,"role":60,"phone":36,"phoneExt":36,"email":36},"Jacob Aelion",{"facility":171,"status":41,"city":172,"state":173,"zip":174,"country":45,"countryCode":46,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Accurate Clinical Research","Baytown","Texas","77521",{"type":48,"coordinates":176},[177,178],-94.97743,29.7355,{"lat":178,"lon":177},[181,184],{"name":55,"role":34,"phone":182,"phoneExt":36,"email":183},"832-705-7839","snajammd@accurateclinicalresearch.com",{"name":185,"role":60,"phone":36,"phoneExt":36,"email":36},"Sabeen Najam",{"facility":187,"status":41,"city":188,"state":173,"zip":189,"country":45,"countryCode":46,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Novel Research LLC","Bellaire","77401",{"type":48,"coordinates":191},[192,193],-95.45883,29.70579,{"lat":193,"lon":192},[196,199],{"name":55,"role":34,"phone":197,"phoneExt":36,"email":198},"832-400-2262","wajeeha@novelresearch.net",{"name":200,"role":60,"phone":36,"phoneExt":36,"email":36},"Wajeeha Yousaf",{"facility":202,"status":41,"city":203,"state":173,"zip":204,"country":45,"countryCode":46,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Northwest Houston Arthritis Center","Houston","77090",{"type":48,"coordinates":206},[207,208],-95.36327,29.76328,{"lat":208,"lon":207},[211,214],{"name":55,"role":34,"phone":212,"phoneExt":36,"email":213},"832-834-5627","adnan@novelresearch.net",{"name":215,"role":60,"phone":36,"phoneExt":36,"email":36},"Adnan Peer",{"facility":217,"status":41,"city":218,"state":173,"zip":219,"country":45,"countryCode":46,"cosmosGeoPoint":220,"geoPoint":224,"contacts":225},"West Texas Clinical Research","Lubbock","79424",{"type":48,"coordinates":221},[222,223],-101.85517,33.57786,{"lat":223,"lon":222},[226,229],{"name":55,"role":34,"phone":227,"phoneExt":36,"email":228},"806-993-1040","jitendra.vasandani@yahoo.com",{"name":230,"role":60,"phone":36,"phoneExt":36,"email":36},"Jitendra Vasandani",{"facility":232,"status":41,"city":233,"state":234,"zip":235,"country":236,"countryCode":237,"cosmosGeoPoint":36,"geoPoint":36,"contacts":238},"Mie University Hospital","Tsu, Mie","Mie-ken","514-8507","Japan","JP",[239,242],{"name":55,"role":34,"phone":240,"phoneExt":36,"email":241},"81 (0) 59-231-5025","yamake@clin.medic.mie-u.ac.jp",{"name":243,"role":60,"phone":36,"phoneExt":36,"email":36},"Keiichi Yamanaka",{"facility":245,"status":41,"city":246,"state":247,"zip":248,"country":236,"countryCode":237,"cosmosGeoPoint":36,"geoPoint":36,"contacts":249},"St. Luke's International Hospital","Chuo-ku","Tokyo","104-8560",[250,253],{"name":55,"role":34,"phone":251,"phoneExt":36,"email":252},"+81 3-3541-5151","satoshi.kawaai@gmail.com",{"name":254,"role":60,"phone":36,"phoneExt":36,"email":36},"Satoshi Kawaai",{"facility":256,"status":41,"city":257,"state":247,"zip":258,"country":236,"countryCode":237,"cosmosGeoPoint":36,"geoPoint":36,"contacts":259},"National Hospital Organization Tokyo Medical Center","Meguro-Ku","152-8902",[260,263],{"name":55,"role":34,"phone":261,"phoneExt":36,"email":262},"81 3-3411-0111","katsuyas.ntmc@gmail.com",{"name":264,"role":60,"phone":36,"phoneExt":36,"email":36},"Katsuya Suzuki",{"facility":266,"status":41,"city":267,"state":36,"zip":268,"country":269,"countryCode":270,"cosmosGeoPoint":271,"geoPoint":275,"contacts":276},"Centro Reumatologico de Caguas","Caguas","00725","Puerto Rico","PR",{"type":48,"coordinates":272},[273,274],-66.0485,18.23412,{"lat":274,"lon":273},[277,280],{"name":55,"role":34,"phone":278,"phoneExt":36,"email":279},"787-414-8465","ajperez@crcsalud.com",{"name":281,"role":60,"phone":36,"phoneExt":36,"email":36},"Amarilis Perez De Jesus",{"type":283,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR","100614935","phase-3-continuation-study-of-zasocitinib-in-adults-with-psoriatic-arthritis-100614935",false,"NCT07286058","Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis","A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs","Inclusion Criteria:\n\n1. The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is \\>=19 years of age.\n2. The participant has completed the 52-week treatment period in one of the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002) independent of treatment assignment, and without meeting the criteria for permanent discontinuation of trial intervention defined in the parent studies.\n3. The participant must be deemed by the investigator to benefit from continued or newly initiated (that is, for participants randomized to active comparator in parent study TAK-279-PsA-3001) zasocitinib therapy.\n\nExclusion Criteria:\n\n1. Any participant who is deemed by the investigator to be not benefiting from the trial intervention based upon lack of improvement or worsening of their symptoms in the respective parent study.\n2. Any participant who met the criteria for permanent discontinuation of trial intervention defined in the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002).\n3. The participant has developed any disease(s) that might confound the evaluations of benefit of zasocitinib therapy since enrollment in the respective parent study, including but not limited to rheumatoid arthritis, axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia.\n4. The participant has developed evidence of a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).","ALL","18 Years",{"count":294,"type":295},1182,"ESTIMATED","INTERVENTIONAL",[298],"PHASE3","Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin.\n\nThe purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time.\n\nAdults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 \\[NCT06671483\\] or TAK-279-PsA-3002 \\[NCT06671496\\]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD).\n\nEach participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.",[301],"Psoriatic Arthritis",[303,304,305],"Drug Therapy","Latitude PsA","Latitude PsA-3003","2026-06-16",{"date":308,"type":309},"2026-06-17","ACTUAL",{"date":311,"type":309},"2026-03-11",{"date":313,"type":295},"2029-12-18",{"name":5,"class":6},16]